CCL

Összesen 2 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM040271
Első szerző:Chinoy, Hector
Cím:Interaction of HLA-DRB1*03 and smoking for the development of anti-Jo-1 antibodies in adult idiopathic inflammatory myopathies : a European-wide case study / Chinoy H., Adimulam S., Marriage F., New P., Vincze M., Zilahi E., Kapitány A., Gyetvai A., Ekholm L., Novota P., Remakova M., Charles P., McHugh N. J., Padyukov L., Alfredsson L., Vencovsky J., Lundberg I. E., Danko K., Ollier W. E., Cooper R. G.
Dátum:2012
Megjegyzések:Objectives: HLA-DRB1*03 is strongly associated withanti-Jo-1-positive idiopathic infl ammatory myopathies (IIM)and there is now increasing evidence that Jo-1 antigen ispreferentially expressed in lung tissue. This study examinedwhether smoking was associated with the development ofanti-Jo-1 antibodies in HLA-DRB1*03-positive IIM.Methods IIM cases were selected with concurrentinformation regarding HLA-DRB1 status, smoking historyand anti-Jo-1 antibody status. DNA was genotypedat DRB1 using a commercial sequence-specifi coligonucleotide kit. Anti-Jo-1 antibody status wasestablished using a line blot assay or immunoprecipitation.Results 557 Caucasian IIM patients were recruited fromHungary (181), UK (99), Sweden (94) and Czech Republic(183). Smoking frequency was increased in anti-Jo-1-positive IIM cases, and reached statistical signifi cance inHungarian IIM (45% Jo-1-positive vs 17% Jo-1-negative,OR 3.94, 95% CI 1.53 to 9.89, p<0.0001). A strongassociation between HLA-DRB1*03 and anti-Jo-1status was observed across all four cohorts (DRB1*03frequency: 74% Jo-1-positive vs 35% Jo-1-negative, OR5.55, 95% CI 3.42 to 9.14, p<0.0001). The frequency ofHLA-DRB1*03 was increased in smokers. The frequencyof anti-Jo-1 was increased in DRB1*03-positive smokersvs DRB1*03-negative non-smokers (42% vs 8%, OR 7.75,95% CI 4.21 to 14.28, p<0.0001) and DRB1*03-positivenon-smokers (42% vs 31%, p=0.08). In DRB1*03-negative patients, anti-Jo-1 status between smokers andnon-smokers was not signifi cantly different. No signifi cantinteraction was noted between smoking and DRB1*03status using anti-Jo-1 as the outcome measure.Conclusion Smoking appears to be associated withan increased risk of possession of anti-Jo-1 in HLADRB1*03-positive IIM cases. The authors hypothesisethat an interaction between HLA-DRB1*03 and smokingmay prime the development of anti-Jo-1 antibodies.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
myopathy
Megjelenés:Annals of the Rheumatic Diseases 71 : 6 (2012), p. 961-965. -
További szerzők:Adimulam, S. Marriage, F. New, Paul Nagy-Vincze Melinda (1985-) (orvos) Zilahi Erika (1964-) (molekuláris biológus) Kapitány Anikó (1979-) (molekuláris biológus) Gyetvai Ágnes Ekholm, L. Novota, P. Remakova, M. Charles, Peter McHugh, Neil Padyukov, Leonid Alfredsson, Lars Vencovsky, Jiri Lundberg, Ingrid Dankó Katalin (1952-2021) (belgyógyász, allergológus és klinikai immunológus) Ollier, William E. Cooper, Robert G.
Internet cím:DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM028786
Első szerző:Váróczy László (belgyógyász, haematológus)
Cím:Fc-gamma-receptor IIIa polymorphism and gene expression profile do not predict the prognosis in diffuse large B-cell lymphoma treated with R-CHOP protocol / László Váróczy, Erika Zilahi, Ágnes Gyetvai, Béla Kajtár, Lajos Gergely, Sándor Sipka, Árpád Illés
Dátum:2012
ISSN:1219-4956
Megjegyzések:The addition of rituximab to conventional chemotherapy has significantly improved the treatment outcome in diffuse large B-cell lymphoma. However, differences in treatment response and survival data can be observed independently from the International Prognostic Index scores. The current study evaluated the impact of Fc-gamma-receptor IIIa polymorphism and gene expression profile on the response of DLBCL patients to R-CHOP therapy as well as on their survival results. Fifty-one patients were involved, thirty-two females, nineteen males, their median age was 53.1 years. The FCGR3A polymorphism at the 158. amino acid position determined with PCR method showed the following results: VV: 12 cases (23.5%), VF: 29 cases (56.8%) and FF: 10 cases (19.6%), respectively. There was no significant difference between the treatment responses of the three groups. The event-free survival data were less favorable in the F-allele carriers than in V/V homozygous patients, but without any significancy, and the overall survival curves were almost the same. As for the gene expression profile, 20 patients' biopsy specimens showed germinal center and 31 showed non-germinal center characteristics. Treatment results did not differ from each other in the two groups. Both the event-free and the overall survival data were more favorable in the GC group, however the differences were not significant. Our results contest the predictive value of Fc-gamma-receptor IIIa polymorphism and gene expression profile in diffuse large B-cell lymphoma.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Diffuse large B-cell lymphoma
Rituximab
Fc-gamma-receptor IIIa polymorphism
Gene expression profile
Treatment response
Survival
egyetemen (Magyarországon) készült közlemény
Megjelenés:Pathology and Oncology Research 18 : 1 (2012), p. 43-48. -
További szerzők:Zilahi Erika (1964-) (molekuláris biológus) Gyetvai Ágnes Kajtár Béla (1977-) (patológus) Gergely Lajos (1965-) (belgyógyász, haematológus) Sipka Sándor (1945-) (laboratóriumi szakorvos) Illés Árpád (1959-) (belgyógyász, haematológus, onkológus)
Pályázati támogatás:MECANTURA
Egyéb
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1